The combined platform brings together digital slide scanning and AI-powered precision pathology software to accelerate accessible and scalable adoption of precision diagnostics
Grundium Oy, a leader in advanced digital scanning backed by the U.S. healthcare private equity firm EW Healthcare Partners, today announced the acquisition of Visiopharm A/S, a leading company in AI-powered precision pathology software. The acquisition represents a significant step in Grundium’s strategy to build a broader digital and computational pathology platform.
The combined business brings together complementary capabilities from Grundium’s advanced imaging platform and Visiopharm’s AI-powered precision pathology software, creating an accessible end-to-end solution for diagnostic labs, biopharma development, and research.
As precision diagnostics advance, digital pathology enables clinicians, researchers, and labs to access accurate and reproducible biomarker assessments while managing increasing workloads and complexity. The combined platform addresses these challenges by enabling more efficient and scalable digital pathology, while expanding access through compact scanning solutions that reduce costs and remove infrastructure barriers.
By combining Grundium’s scanner portfolio with Visiopharm’s AI-powered software, the platform supports a wide variety of use cases, from individual lab workflows to enterprise-scale deployments, biomarker development, translational research, clinical studies, and companion diagnostics programs.
Grundium and Visiopharm had already worked together by integrating their solutions for laboratories, and the acquisition further strengthens this already established collaboration.
For existing customers and partners, continuity remains a priority. Grundium’s digital scanners and Visiopharm’s precision pathology software will continue to be available and supported independently, allowing customers to continue with their current solutions or combine capabilities as their needs evolve.
"Precision medicine starts with precision pathology," said Mika Kuisma, CEO of Grundium. "By combining Grundium's imaging technologies with Visiopharm's advanced AI applications, we are creating a stronger foundation for clinicians and labs to adopt high-value workflows and scale them over time. Together, we can help make precision pathology more accessible, practical, and transformative for customers worldwide."
"Grundium and Visiopharm bring highly complementary capabilities," said Michael Grunkin, CEO of Visiopharm. "This combination allows us to connect biomarker analysis, imaging, and quality management in new ways, while continuing to support the software and workflows our customers rely on today. Together, we are better positioned to support the next phase of precision diagnostics."
"When we invested in Grundium, our thesis was to create a differentiated digital pathology platform," said Evis Hursever, CEO and Managing Director of EW Healthcare Partners. "The acquisition of Visiopharm is a transformative step, adding leading AI capabilities and accelerating Grundium's evolution into a comprehensive platform that will deliver better insights to clinicians, researchers, and patients."
"Digital pathology has the potential to dramatically improve diagnostic accuracy, workflow efficiency, and global access to specialized care. The platform we are building brings these capabilities together to make diagnostics faster, more reliable, and efficient, transforming patient care and supporting the development of revolutionary new treatments, especially in oncology," said Andy Thomson, Operating Partner at EW Healthcare Partners and Chairman of the Board of Grundium.
About Grundium
Grundium, a global leader in digital pathology imaging technology, drives access to digital pathology with slide scanning solutions designed for demanding professional workflows. Founded in 2015 by former Nokia engineers, the Finnish company develops compact, high-quality scanners for healthcare, educational, and research environments. Based on over 20 years of experience in optics, sensors, and precision device engineering, Grundium's imaging solutions combine advanced technology with intuitive ease of use and exceptional design.
About Visiopharm
Visiopharm is a leading provider of AI-driven precision pathology software for research, diagnostics, and biopharmaceutical services. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader in clinical applications, with no less than nine diagnostic algorithms approved under IVDR for EU and UK customers. Founded in 2002, Denmark-based Visiopharm operates internationally with over 750 customer accounts in more than 40 countries.
About EW Healthcare Partners
With over $2 billion of capital raised since 2014, EW Healthcare Partners seeks to make growth equity investments in fast-growing, commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostic, and technology-enabled services sectors in the United States and Europe. EW Healthcare Partners maintains an exclusive commitment to the healthcare industry and has been a long-term investor in numerous healthcare companies across various segments, stages, and geographies. The team of senior investment professionals, operating partners, and advisors is based in New York, London, and Houston. For more information, visit https://www.ewhealthcare.com